Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA cancer policy office

This article was originally published in The Gray Sheet

Executive Summary

Review of therapeutic biologics and drugs for oncology imaging will be consolidated by a new office within FDA's Center for Drug Evaluation & Research. The Office of Oncology Drug Products will engage in policy development, provide technical consultation to FDA's device center, and serve as a point of contact for cancer professional organizations, the National Cancer Institute and stakeholders, FDA announces July 16. Recruitment of a director will begin this summer; the reorganization wrap-up is slated for the first half of 2005...

You may also be interested in...



Oncology office seeks director

FDA is searching for a director of the newly formed Office of Oncology Drug Products. The agency is targeting candidates "outside as well as from inside the government," Acting Commissioner Lester Crawford states at an Aug. 2 National Press Club luncheon in Washington, D.C. Crawford called the job "appealing," and told the audience that the director would "be able to define this exciting new position." The new division will combine current review divisions for imaging agents, biologics and oncology drugs. The hire likely will coincide with a new, formal partnership with the National Cancer Institute (1"The Gray Sheet" July 19, 2004, In Brief)...

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.

P&G Causes Friction With UK Cosmetics Firm Over Ad Claim

Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.

UsernamePublicRestriction

Register

MT020580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel